Status:
RECRUITING
International Leukemia Target Board
Lead Sponsor:
Princess Maxima Center for Pediatric Oncology
Conditions:
Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy
Eligibility:
All Genders
Up to 25 years
Brief Summary
The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform se...
Detailed Description
Improvements in outcome for pediatric hematological malignancies have mainly been driven by the optimization of multi-agent chemotherapy regimens, minimal residual disease monitoring, and risk group s...
Eligibility Criteria
Inclusion
- Inclusion criteria
- The patient has been diagnosed with a R/R hematological malignancy;
- The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy;
- The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment;
- The patients' life expectancy is at least 6 weeks;
- The patient has undergone any sort of molecular profiling of his/her tumor and the re-sults of this analysis are available;
- The patient has undergone flow cytometry in a certified lab and results are available;
- Written informed consent of patient and/or parent(s)/guardian(s) to discuss the patient in the iLTB according to local law and legislation has been obtained.
- Exclusion criteria: none defined
Exclusion
Key Trial Info
Start Date :
December 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2032
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05270096
Start Date
December 31 2022
End Date
June 1 2032
Last Update
January 9 2026
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Gent
Ghent, Belgium
2
Righospitalet
Copenhagen, Denmark
3
Semmelweis
Budapest, Hungary
4
Princess Máxima Center for Pediatric Oncology
Utrecht, Utrecht, Netherlands, 3584CS